Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Sight Sciences (SGHT) EBITDA (2020 - 2025)

Historic EBITDA for Sight Sciences (SGHT) over the last 6 years, with Q3 2025 value amounting to -$7.9 million.

  • Sight Sciences' EBITDA rose 2960.19% to -$7.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$45.4 million, marking a year-over-year increase of 875.63%. This contributed to the annual value of -$50.5 million for FY2024, which is 1177.15% up from last year.
  • Per Sight Sciences' latest filing, its EBITDA stood at -$7.9 million for Q3 2025, which was up 2960.19% from -$11.7 million recorded in Q2 2025.
  • Sight Sciences' 5-year EBITDA high stood at -$7.9 million for Q3 2025, and its period low was -$22.9 million during Q2 2022.
  • Moreover, its 5-year median value for EBITDA was -$13.9 million (2025), whereas its average is -$14.6 million.
  • As far as peak fluctuations go, Sight Sciences' EBITDA crashed by 10642.83% in 2022, and later soared by 3860.84% in 2023.
  • Quarter analysis of 5 years shows Sight Sciences' EBITDA stood at -$14.7 million in 2021, then decreased by 15.88% to -$17.1 million in 2022, then skyrocketed by 34.85% to -$11.1 million in 2023, then fell by 7.37% to -$11.9 million in 2024, then soared by 33.73% to -$7.9 million in 2025.
  • Its EBITDA was -$7.9 million in Q3 2025, compared to -$11.7 million in Q2 2025 and -$13.9 million in Q1 2025.